[Bone density before and after the hormonal therapy of young women with hypergonadotropic hypogonadal amenorrhea].
Dual energy X-ray absorptiometry of bone density in the lumbar vertebral column was performed in 32 young women (mean age 24.6 [19-34] years) with hypergonadotropic hypogonadal amenorrhoea. There was a significantly lower bone density (0.74 +/- 0.27 g/cm2) than in a control group of 27 women of similar age (1.17 +/- 0.081 g/cm2; P less than 0.001). Subsequently 21 of the 32 women received cyclical hormone substitution therapy for 24 months (day 1-30: 0.625 mg conjugated oestrogens; additionally, on days 20-30: 5 mg medrogestone; followed by a seven-day pause). After 6 months bone density, compared with that of the 11 untreated women, had increased significantly (P less than 0.001). It is therefore recommended that young hypoestrogenemic women should receive early and continuous hormone substitution treatment.
Holzer
G
G
Menox Ambulatorium, Wien.
Metka
M
M
Heytmanek
G
G
Knogler
W
W
Huber
J
J
D015502:Absorptiometry, Photon / Q000295:instrumentation / Q000379:methods; D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000188:drug therapy*; D015519:Bone Density / Q000187:drug effects*; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood; D045166:Estradiol Congeners / Q000008:administration & dosage*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D008524:Medrogestone / Q000008:administration & dosage*; D013997:Time Factors
D045166:Estradiol Congeners; D008524:Medrogestone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
Knochendichte vor und nach Hormontherapie bei jungen Frauen mit hypergonadotroper hypogonader Amenorrhoe.